Registry-Based Surveillance of Medical-Device Safety M edical devices have revolutionized health care, but assurance of their postmarketing safety relies on voluntary reporting of adverse events. This system has resulted in incomplete ascertainment and an inability to evaluate the safety of medical devices in an active, prospective fashion. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Early identification of real-world differences in clinical performance among medical devices may provide opportunities to support iterative improvements in device design and complement traditional premarketing evidence to refine the selection of patients and improve the training of providers. Active surveillance of medical-device safety, through the continuous monitoring of large clinical-data sources, has been proposed to address these limitations [13] [14] [15] and has been identified as a priority by the Food and Drug Administration (FDA). 16 This study was designed to evaluate a strategy of active surveillance of a national cardiovascular registry for assessment of the postmarketing safety of an implantable vascular-closure device. To test this strategy, we considered implantable devices for which previous reports had identified potential safety concerns. Previous studies had suggested important differences between the rates of complications after implantation of one vascularclosure device (Mynx, Cardinal Health) and the rates after implantation of alternative vascularclosure devices following percutaneous coronary intervention (PCI) and cardiac catheterization procedures performed through the femoral artery. 13, 17 Unlike other vascular-closure devices, which use a variety of mechanical and biomaterial components to help accelerate hemostasis by sealing the arteriotomy site, the Mynx device delivers a polyethylene glycol gel to the surface of the artery without mechanical anchoring. The effect of this design difference on the performance and safety of the Mynx device as compared with other available vascular-closure devices is unknown. We therefore sought to use registry data regarding this device to test our prospective, active data-surveillance strategy.
Me thods

Study Design and Oversight
We used an active clinical-data surveillance system, called DELTA (Data Extraction and Longitudinal Trend Analysis), which prospectively monitors clinical registries and other detailed clinical-data sources for safety signals; we have previously validated this surveillance system. 13, 15, [18] [19] [20] [21] [22] DELTA is a collection of integrated software components linking open-source database management and statistical analysis tools and is designed to simultaneously support multiple risk-adjusted prospective safety-surveillance analyses of complex clinical-data sets. 13, 15 (Additional information regarding DELTA is provided in the Methods section in the Supplementary Appendix, available with the full text of this article at NEJM.org.)
The CathPCI DELTA study was designed to evaluate the feasibility of using the DELTA system for prospective, active surveillance of medicaldevice safety by monitoring clinical outcomes with the identified vascular-closure device after PCI procedures. We used the CathPCI Registry of the National Cardiovascular Data Registry (NCDR) as the data source. We identified the Mynx vascular-closure device as the device of interest on the basis of evidence from previous national-registry and regional studies suggesting that the Mynx device was associated with a higher rate of accesssite bleeding, injury, or need for repeat intervention than were alternative vascular-closure devices. 13, 17 The use of the Mynx device has been increasing since 2012, a factor that highlights the practical clinical importance of such analyses (Fig. S1 in the Supplementary Appendix).
A study oversight committee was established, and a written protocol (available at NEJM.org) was approved before the review of any study data. The protocol includes descriptions of the prespecified end points, analytic methods, sensitivity analyses, and plans for two interim data reviews. The study protocol was reviewed and accepted by the institutional review boards of the NCDR and the Lahey Hospital and Medical Center.
Device Exposures and Adverse Outcomes
We used the CathPCI Registry to identify all the patients who had received a vascular-closure device after PCI from January 1, 2011, to September 30, 2013. We excluded patients who had undergone implantation of an intraaortic balloon pump or ventricular-assist device, those in whom nonfemoral arterial access was used, those in whom more than one vascular-closure device was deployed, and those in whom the vascular-closure device did not have an implantable component. We grouped together vascular-closure devices that have identical mechanisms of action and identi-T h e ne w e ngl a nd jou r na l o f m e dicine cal implanted materials into "device families" in order to increase the analytic power (Table S1 in the Supplementary Appendix).
The primary safety outcome was any vascular complication, which was a composite of access-site bleeding requiring treatment, access-site hematoma requiring treatment, retroperitoneal bleeding, or any vascular complication requiring intervention. Secondary safety end points were access-site bleeding requiring treatment and postprocedural blood transfusion. All end points and covariates were defined according to the terms used in the CathPCI Registry, version 4 (additional details are provided in the Methods section in the Supplementary Appendix). All the outcomes were assessed until the time of hospital discharge on the basis of data that were available from the CathPCI Registry.
Propensity-Score Matching
For each analysis, a propensity-matched concurrent control population was identified on the basis of a nonparsimonious propensity model. The model included previously identified risk factors as well as covariates that we selected on the basis of information from previous studies (see the Methods section in the Supplementary Appendix for details). 13 Variables were excluded if they were found to be colinear with covariates that were already included in the propensity model. We used univariate rules to impute missing data by assuming the absence of a clinical condition for dichotomous variables and by using the median observed value for continuous variables. The final propensity model is provided in Table S2 in the Supplementary Appendix.
Data-Surveillance Process
Fully deidentified case-level data from the CathPCI Registry were provided to DELTA on the basis of scheduled quarterly updates, and the cumulative safety analysis was automatically regenerated within DELTA. Using a fixed caliper width of 0.01 and a greedy-matching algorithm, 10, 15, 23 we matched control patients according to their propensity scores with Mynx recipients in a 1:1 ratio within 6 months before or after the implantation of the Mynx device. We used the absolute standardized difference in means and proportions of covariates to assess the relative imbalance between the exposed and unexposed groups, with values of less than 0.10 considered to be adequately balanced. 24 The primary measure of interest was the relative risk of an adverse safety outcome, which was defined as the ratio of observed event rates in the Mynx-treated patients to those in the matched control population of patients who were treated with other vascular-closure devices. DELTA alerts were triggered if the differences between the independent proportions for the Mynx device and those for the alternative devices were significant, as measured by the Wilson method. 25 We calculated 95% confidence intervals that were corrected for multiple comparisons using the O'Brien-Fleming alpha-spending method adapted for use in prospective surveillance 26 (see the Methods section in the Supplementary Appendix).
Prespecified Subgroup and Sensitivity Analyses
Subgroups of patients who were prespecified as being at high risk included patients with diabetes, those 70 years of age or older, and women. Sensitivity analyses included alternative event-rate estimation with the use of logistic-regression risk adjustment in place of propensity matching.
Interim Review and Additional Analyses
After 9 months of monitoring, an early alert led the study steering committee to recommend that an additional analysis be performed to address potential bias owing to center-level effects. It was hypothesized that higher adverse-event rates might be expected at centers in which the Mynx device was used infrequently, since at such centers the device may have been reserved for patients at higher risk. We therefore performed a propensitymatched analysis that included only patients who had undergone PCI at centers in which the Mynx device was commonly used.
After review of the final study results, the FDA requested an additional analysis using the most recent data collected in the CathPCI Registry to assess the persistence of the DELTA safety signals. A protocol amendment was finalized, and data for the period from October 1, 2013, to September 30, 2015, were made available to DELTA. We recalibrated propensity-score models using data from patients who had undergone PCI from October 1, 2013, through March 31, 2014. An independent propensity-matched analysis was performed for patients who had undergone procedures from April 1, 2014, through September 30, 2015.
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The study steering committee also recommended several post hoc sensitivity analyses to assess the robustness of the primary findings. These analyses included performance of a falsification-hypothesis analysis in which the original matched patient cohorts were evaluated for the development of postprocedural nephropathy associated with the use of iodine as a radiographic contrast agent (contrast-induced nephropathy), which was defined as a maximal increase in the serum creatinine level of at least 25% or at least 0.5 mg per deciliter (44 μmol per liter) over the pre-PCI level. 27 For this outcome, no difference in risk among various vascular-closure devices was expected. Additional sensitivity analyses included alternative approaches to handling missing data, as well as an analysis that used center-level matching, rather than global-registry matching, in an effort to address any confounding from centerlevel effects. Analyses similar to the analysis performed for the Mynx device were performed for three other commonly used vascular-closure devices. Finally, we compared event rates associated with vascular-closure devices with the rates associated with manual or mechanical access-site compression for hemostasis. Additional details regarding the analytic methods and assumptions are provided in the Methods section in the Supplementary Appendix.
R esult s
Study Population
From January 1, 2011, through September 30, 2013, a total of 1,822,575 patients underwent PCI and had data submitted to the CathPCI Registry; of these patients, 73,164 received the Mynx vascular-closure device and met the inclusion criteria for the analysis (Fig. S2 in the Supplementary Appendix). The amount of missing data did not differ significantly between the patients who received the Mynx vascular-closure device and those who received alternative vascular-closure devices and represented 0.04% of all risk-factor data (Table S3 in the Supplementary Appendix). Propensity matching resulted in the successful matching of 73,124 patients (99.9%) who had received Mynx devices with patients who had received alternative devices (Table 1) . Matching resulted in an adequate distribution of risk factors between the cohorts, with all post-matching standardized differences less than 0.10 (the threshold for imbalance).
Safety Alerts for Mynx Devices
After 9 months of monitoring for the primary outcome of any vascular complication, a DELTA alert was triggered and was sustained throughout the duration of the surveillance study ( Fig. 1) . At the end of the study, the absolute risk of a vascular complication was 1.2% in the group that received the Mynx device and 0.8% in the group that received an alternative vascular-closure device (relative risk, 1.59; 95% confidence interval [CI], 1.42 to 1.78; P<0.001). Each component of the primary safety outcome was significantly more common in the group that received the Mynx device, including the risk of major access-site bleeding, vascular complication requiring intervention, access-site hematoma, and postprocedural retroperitoneal bleeding. In addition, there was a significantly increased risk of both secondary safety end points, including the rate of access-site bleeding (absolute risk, 0.4% vs. 0.3%; relative risk, 1.34; 95% CI, 1.10 to 1.62; P = 0.001) and transfusion (absolute risk, 1.8% vs. 1.5%; relative risk, 1.23; 95% CI, 1.13 to 1.34; P<0.001). The alerts for the secondary end points of major access-site bleeding and postprocedural blood transfusion were triggered after 30 months and 15 months, respectively, and were sustained throughout the remainder of the surveillance period (Table 2) .
Prespecified Subgroup and Sensitivity Analyses
Protocol-specified propensity-matched analyses were performed for high-risk subgroups: patients with diabetes, those 70 years of age or older, and women (Table 2 ). More than 99% of the identified patients were successfully matched within each subgroup, which resulted in the inclusion of more than 25,000 patients receiving Mynx devices in each high-risk subgroup. Within 15 months after the initiation of monitoring, safety alerts for vascular complications were triggered for all subgroups and were sustained for the duration of the study. The relative risks of any vascular complication ranged from 1.72 (95% CI, 1.42 to 2.10) among patients with diabetes to 1.94 (95% CI, 1.63 to 2.29) among those who were 70 years of age or older (Fig. 2) .
In a prespecified sensitivity analysis, a logistic model was used to adjust for baseline risk in place of propensity matching. This analysis confirmed safety alerts for primary and secondary outcomes within 27 months after the initiation 4 . NSTEMI denotes non-ST-segment elevation myocardial infarction, and PCI percutaneous coronary intervention. † The standardized difference (i.e., the mean between-group difference divided by the standard deviation) was calculated to assess the relative imbalance between the exposed and unexposed groups, with values of less than 0.100 considered to be adequately balanced. The standardized difference for unmatched exposures compared these patients with those who had received the Mynx device and were included in the propensity matching. ‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
Registry-Based Surveillance of Medical-Device Safety of safety surveillance, thereby supporting the primary results (Table S4 in the Supplementary Appendix).
Post Hoc Analysis at Mynx High-Use Centers
We identified 28,141 patients who had received Mynx devices at hospitals in which Mynx devices were used most frequently among available vascular-closure devices (Table 3 ). More than 99% of these patients (28,107) were matched with those receiving the Angio-Seal vascular-closure device at centers in which that device was preferentially used. A safety alert for vascular complications with the Mynx device was triggered after the first 12 months of monitoring, with a relative risk of 1.43 (95% CI, 1.18 to 1.73). Safety alerts were triggered for the secondary end points of access-site bleeding and transfusion within 21 months after the initiation of surveillance, and all safety alerts persisted throughout the monitoring period.
Post Hoc Signal-Persistence Analysis
At the request of the FDA, we analyzed 49,037 additional PCI procedures in which the Mynx device was used from April 1, 2014, to September 30, 2015, to assess the persistence of the potential safety signal identified in the primary analysis. Of the patients who had undergone these procedures, 48,992 (99.9%) were successfully matched with patients who had received alternative vascularclosure devices, and DELTA alerts were triggered within 12 months for all end points (Table 3, and  Table S5 in the Supplementary Appendix).
Additional Post Hoc Sensitivity Analyses
Repeating the primary analysis with the use of multivariate normal imputation 28 in place of simple imputation rules for missing data did not lead to any significant change in the timing of the safety alerts or estimated relative risks. Separately, to assess potential confounding owing to betweencenter differences, we repeated the primary analysis with patient matching performed at the center level. Using the same propensity-matching methods, we successfully matched 35,192 patients (48.1%) who had received Mynx devices and found a relative risk of vascular complications of 1.59 (95% CI, 1.40 to 1.78). We found no significant differences in estimated relative risk for any outcome or patient subgroup when we used centerlevel matching.
We performed a falsification-hypothesis analysis using the outcome of contrast-induced nephropathy, which was not anticipated to differ between the two groups. The relative risk of contrast-induced nephropathy in the group that received the Mynx device was 1.05 (95% CI, 0.99 to 1.11; P = 0.07), which showed that the risk was slightly but nonsignificantly higher in the group that received the Mynx device (Table 3, (Table S6 in the Supplementary Appendix), whereas manual or mechanical compression was associated with a higher risk of vascular complications than the Mynx device or any vascularclosure device (Table S7 in 1.32%
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Discussion
In our study, we evaluated the feasibility of applying active surveillance to assess the safety of a commonly used vascular-closure device through prospective monitoring of a national clinical registry. We used a prespecified, active surveillance plan to monitor data from the CathPCI Registry to assess the relative safety of a vascular-closure device that was suspected of having increased safety risks over a 3-year study period. Our analysis showed a significantly higher risk of vascular complications, access-site bleeding, and transfusion requirement after PCI among patients treated with the Mynx vascular-closure device than among those treated with alternative vascular-closure devices, although the absolute risk differences were small. Among patients who received the Mynx device, alerts were triggered early, persisted throughout the duration of surveillance, and were present in all subgroups of patients. In addition, the primary results were confirmed in an independent, more contemporary cohort of patients. Analyses of other vascular-closure devices did not show the triggering of similar safety signals.
In an analysis that was restricted to centers that preferentially used the Mynx device among available vascular-closure devices, we found a slightly lower rate of safety alerts than that in the primary analysis, although the between-group difference persisted. These findings suggest that a portion of the difference in complications may be attributed to center-level experience in using the Mynx device, a finding that has been 
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shown previously with other vascular-closure devices. 29 Potential safety signals that are generated through active surveillance should be interpreted with caution, since all such analyses are observational by design. Despite robust risk adjustment through propensity matching, such analyses cannot exclude the possibility that residual confounding is responsible for some portion of the observed difference in adverse events between the Mynx device and alternative vascular-closure devices. The limited number of covariates that were selected for inclusion in the propensity model could contribute to such residual confounding, although the strategy for selecting covariates that was used in this study guarded against overfitting of the models. In addition, important clinical variables such as the anatomical location of the puncture site may have contributed to confounding of the observed relationships, but information on such variables was not available in the CathPCI Registry. Although the duration of follow-up after the PCI procedure was limited to in-hospital events, the adverse events of interest would generally be expected to occur during the index hospitalization. 
Observed event rate (%)
We attempted to assess for residual confounding through several post hoc sensitivity analyses. Although the data set was large, only a small percentage of missing data (<0.04%) was imputed, with the use of simple imputation and with the use of multivariate normal imputation. Case-control matching of patients in a global registry, as was used in this study, may bias results, in that patients who are treated at different centers may have different unmeasured clinical characteristics. However, in an analysis that used center-specific matching, there were no significant changes in the estimated risk differences between the Mynx device and alternative vascular-closure devices.
Finally, we performed a falsification-hypothesis analysis in which we monitored the registry for the development of contrast-induced nephropathy after PCI, although we did not anticipate that there would be an association of this adverse outcome with exposure to a particular vascularclosure device. We found that the risk of contrastinduced nephropathy was slightly but nonsignificantly higher among Mynx recipients, which indicates the possibility of a small amount of residual risk imbalance between Mynx recipients and patients treated with alternative vascularclosure devices.
In conclusion, a strategy of prospective, active surveillance of a representative clinical registry rapidly identified potential safety signals among recipients of an implantable vascular-closure device after PCI. The initial safety alerts occurred within the first 12 months of prospective registry monitoring. † To assess the persistence of the potential safety signal identified in the primary analysis, a further analysis was performed on an additional 49,037 PCI procedures in which the Mynx device was used from April 1, 2014, to September 30, 2015. ‡ A falsification-hypothesis analysis was performed as one of several post hoc sensitivity analyses to assess the robustness of the primary findings. In the falsification-hypothesis analysis, the original matched patient cohorts were evaluated for the development of postprocedural nephropathy that was associated with the use of iodine as a radiographic contrast agent (contrast-induced nephropathy). 
